Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma.

Epeldegui M, Martínez-Maza O.

For Immunopathol Dis Therap. 2015;6(1-2):79-90. doi: 10.1615/ForumImmunDisTher.2016014177.

2.

Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Levin LI, Breen EC, Birmann BM, Batista JL, Magpantay LI, Li Y, Ambinder RF, Mueller NE, Martínez-Maza O.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1114-1123. doi: 10.1158/1055-9965.EPI-16-1012. Epub 2017 Mar 24.

PMID:
28341757
3.

MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the Multicenter AIDS Cohort Study.

Peckham-Gregory EC, Thapa DR, Martinson J, Duggal P, Penugonda S, Bream JH, Chang PY, Dandekar S, Chang SC, Detels R, Martínez-Maza O, Zhang ZF, Hussain SK.

Cancer Epidemiol. 2016 Dec;45:47-57. doi: 10.1016/j.canep.2016.09.007. Epub 2016 Oct 1.

PMID:
27701053
4.

Host factors associated with serologic inflammatory markers assessed using multiplex assays.

McKay HS, Bream JH, Margolick JB, Martínez-Maza O, Phair JP, Rinaldo CR, Abraham AG, Jacobson LP.

Cytokine. 2016 Sep;85:71-9. doi: 10.1016/j.cyto.2016.05.016. Epub 2016 Jun 10.

5.

Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Epeldegui M, Lee JY, Martínez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martínez-Maza O.

Clin Cancer Res. 2016 Jan 15;22(2):328-36. doi: 10.1158/1078-0432.CCR-14-0466. Epub 2015 Sep 17.

6.

Lack of Association between Interleukin-10 Gene Promoter Polymorphisms with HIV Susceptibility and Progression to AIDS.

Ramezani A, Kalantar E, Aghakhani A, Banifazl M, Foroughi M, Hosseini S, Eslamifar A, Esmaeilzadeh A, Mohraz M.

Iran J Pathol. 2015 Spring;10(2):141-8.

7.

Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma.

Saxena R, Kaur J.

World J Hepatol. 2015 Jun 18;7(11):1572-80. doi: 10.4254/wjh.v7.i11.1572. Review.

8.

Association of interleukin-10 with hepatitis B virus (HBV) mediated disease progression in Indian population.

Saxena R, Chawla YK, Verma I, Kaur J.

Indian J Med Res. 2014 May;139(5):737-45.

9.

Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma.

Nolen BM, Breen EC, Bream JH, Jenkins FJ, Kingsley LA, Rinaldo CR, Lokshin AE.

PLoS One. 2014 Jun 12;9(6):e99144. doi: 10.1371/journal.pone.0099144. eCollection 2014.

10.
11.

Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.

Vendrame E, Hussain SK, Breen EC, Magpantay LI, Widney DP, Jacobson LP, Variakojis D, Knowlton ER, Bream JH, Ambinder RF, Detels R, Martínez-Maza O.

Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):343-9. doi: 10.1158/1055-9965.EPI-13-0714. Epub 2013 Nov 12.

12.

B cell lymphoma in HIV transgenic mice.

Curreli S, Krishnan S, Reitz M, Lunardi-Iskandar Y, Lafferty MK, Garzino-Demo A, Zella D, Gallo RC, Bryant J.

Retrovirology. 2013 Aug 28;10:92. doi: 10.1186/1742-4690-10-92.

13.

Immune surveillance and lymphoid malignancy in immunocompromised host.

Stevens PL, Reddy NM.

Am J Blood Res. 2013 May 5;3(2):91-101. Print 2013.

14.

IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations.

Hosgood HD 3rd, Au WY, Kim HN, Liu J, Hu W, Tse J, Song B, Wong KF, Lee JJ, Chanock SJ, Siu LP, Purdue MP, Shin MH, Yu J, Liang R, Kim HJ, Rothman N, Lan Q.

Int J Hematol. 2013 Jun;97(6):793-9. doi: 10.1007/s12185-013-1345-5. Epub 2013 May 3.

15.

Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort.

Conroy SM, Maskarinec G, Morimoto Y, Franke AA, Cooney RV, Wilkens LR, Goodman MT, Hernadez BY, Le Marchand L, Henderson BE, Kolonel LN.

Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):337-47. doi: 10.1158/1055-9965.EPI-12-0947. Epub 2013 Jan 8.

16.

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.

Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, Cerhan JR, Novak AJ.

Cytokine. 2012 Dec;60(3):882-9. doi: 10.1016/j.cyto.2012.08.028. Epub 2012 Sep 23.

17.

Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Keating SM, Jacobs ES, Norris PJ.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):193-206. doi: 10.1016/j.cytogfr.2012.05.006. Epub 2012 Jun 27. Review.

18.

Occupational solvent exposure, genetic variation in immune genes, and the risk for non-Hodgkin lymphoma.

Deng Q, Zheng T, Lan Q, Lan Y, Holford T, Chen Y, Dai M, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y.

Eur J Cancer Prev. 2013 Jan;22(1):77-82. doi: 10.1097/CEJ.0b013e328354d2c1.

19.

Circulating cytokine levels, Epstein-Barr viremia, and risk of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma.

Rabkin CS, Engels EA, Landgren O, Schuurman R, Camargo MC, Ruth Pfeiffer, Goedert JJ.

Am J Hematol. 2011 Oct;86(10):875-8. No abstract available.

20.

HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.

Chao C, Xu L, Abrams DI, Towner WJ, Horberg MA, Leyden WA, Silverberg MJ.

AIDS. 2011 Sep 10;25(14):1771-7. doi: 10.1097/QAD.0b013e328349c67a.

Supplemental Content

Support Center